Published on : Jun 25, 2018
Albany, New York, June 25, 2018: In vitro diagnostics such as urine and blood samples tests are critical in health assessment. To facilitate unbiased in vitro tests, healthcare industry is fast adopting accurate in vitro test reagent kit including specific instruments and systems that render superior results. Leading pharmaceutical companies are exploring new techniques to evolve their product offerings. DiaSorin S.p.A (DIA) a leading biotechnological company has an elaborate profile of pipeline devices that can revolutionize in vitro diagnostics. Market Research Hub (MRH) enumerates the impact of recent developments on DiaSorin product pipeline in its recent report titled, ‘DiaSorin S.p.A (DIA) - Product Pipeline Analysis, 2018 Update’
Advances in Immunodiagnostics and Molecular Diagnostics Accelerate In Vitro Diagnostics
To streamline test procedures in immunodiagnostics and molecular diagnostics, DiaSorin S.p.A (DIA) has diverted investments in in-depth research activities and clinical trials to evolve in vitro diagnostic devices. Several products are at various stages of development which can revolutionize in vitro diagnostics post commercialization. To facilitate auto diagnostics, DiaSorin S.p.A (DIA) develops reagent devices and kits on advanced technology such as Radioimmunometry (RIA), Enzyme Linked Immunosorbent Assays (ELISA) and Chemiluminescence (CLIA).
In a recent development, DiaSorin has disclosed about its path breaking achievement in attaining FDA clearance for Simplexa® HSV 1 & 2 Direct assay used to diagnose HSV 1 and 2. This development facilitates an increased number of samples that can be subject to test pertaining to genital swabs and mucocutaneous swab samples. With this addition, Diasorin holds a diverse sample coverahe for HSV 1 and 2 tests. Simplexa® HSV 1 & 2 is a real time PCR assay which is compatible with DiaSorin’s Liason MDX instrument. The instrument eliminates DNA extraction as part of the procedure and carries out roughly eight sample readings in less than an hour.
Additionally, DiaSorin has also added a total of three new primer pairs of reagents that will aid laboratory molecular tests. These reagents will improve diagnosis of tick borne samples and aid apt molecular tests and eventual therapeutics.
Thorough research findings compiled in the report present an illustrative overview of several products that are in DiaSorin S.p.A (DIA) pipeline. DiaSorin S.p.A (DIA) invests in in vitro reagent kit innovation targeting several disciplines. Some of the key segments in which the company develops reagent kit include, hypertension, cardiac diseases, endocrinology, oncology, bone and mineral disorders, gastrointestinal infections, autoimmune disorders, and neurological diseases. The report components present vital insights about the development of various products that are in pipeline. Some of the key reagent kit that DiaSorin S.p.A envisions to commercialize include, BCR-ABL ABL assay product for detecting leukaemia, C-Kit 816 assay product for detecting cancer, lactoferrin assay product for influenza amongst others.
The report also gives a detailed illustration of geographical presence of DiaSorin S.p.A (DIA). Based on region, DiaSorin S.p.A (DIA) has a global presence in North America, South America, Asia-Pacific, Middle East and Africa, and South Africa. Readers can comprehend major marketing tactics administered by DiaSorin S.p.A in various regions to trigger favorable end-user response.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1833108
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com